Journal of International Psychiatry

[Abstract] Objective: To observe the ziprasidone and olanzapine in patients with schizophrenia in clinical treatment and the safety of glycolipid metabolism. Methods: Ninety patients with schizophrenia were randomly divided into the control group (n = 45) and the observation group (n = 45). The control group was treated with olanzapine, the observation group was treated with ziprasidone, and the blood lipid and blood glucose were measured by automatic biochemical analyzer. The effects of the two groups on glucose and lipid metabolism were compared. Results: PANSS scores of two groups before treatment were not statistically significant (P> 0.05); PANSS score of observation group 3 weeks, 8 weeks after treatment, lower than the control group (P <0.05); 2 groups before treatment TG , TC, HDL and LDL were significantly lower than those in the control group (P <0.05). The levels of TC, TG, HDL and LDL in the observation group were significantly lower than those in the control group at 8 weeks after treatment (P < (P <0.05). There were no significant differences in the incidence of adverse drug reactions between the two groups after treatment (P> 0.05). There was no significant difference in the levels of FBS, INS and IRI between the two groups (P> 0.05). Conclusion: The efficacy of ziprasidone in patients with schizophrenia is ideal. The effect of ziprasidone on the metabolism of glucose in patients with schizophrenia is relatively small and worthy of popularization and application.

【Key words】 ziprasidone; olanzapine; schizophrenia; therapeutic effect; glycolipid metabolism